Cargando…

Fibrosis: a key feature of Fabry disease with potential therapeutic implications

Fabry disease is a rare X-linked hereditary disease caused by mutations in the AGAL gene encoding the lysosomal enzyme alpha-galactosidase A. Enzyme replacement therapy (ERT) is the current cornerstone of Fabry disease management. Involvement of kidney, heart and the central nervous system shortens...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weidemann, Frank, Sanchez-Niño, Maria D, Politei, Juan, Oliveira, João-Paulo, Wanner, Christoph, Warnock, David G, Ortiz, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3750297/ https://www.ncbi.nlm.nih.gov/pubmed/23915644 http://dx.doi.org/10.1186/1750-1172-8-116

Ejemplares similares

Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry
por: Ortiz, Alberto, et al.
Publicado: (2016)

Understanding and modifying Fabry disease: Rationale and design of a pivotal Phase 3 study and results from a patient-reported outcome validation study
por: Wanner, Christoph, et al.
Publicado: (2022)

Use of a rare disease registry for establishing phenotypic classification of previously unassigned GLA variants: a consensus classification system by a multispecialty Fabry disease genotype–phenotype workgroup
por: Germain, Dominique P, et al.
Publicado: (2020)

Association and diagnostic utility of diastolic dysfunction and myocardial fibrosis in patients with Fabry disease
por: Liu, Dan, et al.
Publicado: (2018)

Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease
por: Üçeyler, Nurcan, et al.
Publicado: (2016)

Improvement of gastrointestinal symptoms in a significant proportion of male patients with classic Fabry disease treated with agalsidase beta: A Fabry Registry analysis stratified by phenotype
por: Hopkin, Robert J., et al.
Publicado: (2020)

Kidney function as an underestimated factor for reduced health related quality of life in patients with Fabry disease
por: Wagner, Martin, et al.
Publicado: (2014)

Increased Arterial Diameters in the Posterior Cerebral Circulation in Men with Fabry Disease
por: Üçeyler, Nurcan, et al.
Publicado: (2014)

Left Ventricular Geometry and Blood Pressure as Predictors of Adverse Progression of Fabry Cardiomyopathy
por: Krämer, Johannes, et al.
Publicado: (2015)

Diagnosis and Screening of Patients with Fabry Disease
por: Vardarli, Irfan, et al.
Publicado: (2020)

Late onset variants in Fabry disease: Results in high risk population screenings in Argentina
por: Serebrinsky, G., et al.
Publicado: (2015)

Current and Investigational Therapeutics for Fabry Disease
por: Felis, Andrew, et al.
Publicado: (2019)

Potential role of vitamin D deficiency on Fabry cardiomyopathy
por: Drechsler, Christiane, et al.
Publicado: (2013)

Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease
por: Lenders, Malte, et al.
Publicado: (2016)

Expression of uPAR in Urinary Podocytes of Patients with Fabry Disease
por: Trimarchi, Hernán, et al.
Publicado: (2017)

Fabry disease during the COVID-19 pandemic. Why and how treatment should be continued
por: Politei, Juan
Publicado: (2020)

Chaperone Therapy in Fabry Disease
por: Weidemann, Frank, et al.
Publicado: (2022)

Impaired small fiber conduction in patients with Fabry disease: a neurophysiological case–control study
por: Üçeyler, Nurcan, et al.
Publicado: (2013)

Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation
por: Warnock, David G., et al.
Publicado: (2012)

Fabry Cardiomyopathy: Current Treatment and Future Options
por: Vardarli, Irfan, et al.
Publicado: (2021)

Value of the CHA(2)DS(2)-VASc score and Fabry-specific score for predicting new-onset or recurrent stroke/TIA in Fabry disease patients without atrial fibrillation
por: Liu, Dan, et al.
Publicado: (2018)

Increased urinary CD80 excretion and podocyturia in Fabry disease
por: Trimarchi, H., et al.
Publicado: (2016)

High‐Sensitivity Troponin: A Clinical Blood Biomarker for Staging Cardiomyopathy in Fabry Disease
por: Seydelmann, Nora, et al.
Publicado: (2016)

Fabry disease and COVID-19: International expert recommendations for management based on real-world experience
por: Laney, Dawn A., et al.
Publicado: (2021)

Fabry disease and COVID-19: international expert recommendations for management based on real-world experience
por: Laney, Dawn A, et al.
Publicado: (2020)

Hot topics in Fabry disease
por: Cairns, Tereza, et al.
Publicado: (2018)

Effectiveness of enzyme replacement therapy in Fabry disease: Long term experience in Argentina
por: Cabrera, Gustavo, et al.
Publicado: (2017)

Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant
por: Lenders, Malte, et al.
Publicado: (2016)

Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies
por: El Dib, Regina, et al.
Publicado: (2017)

Fabry Disease Patient-Reported Outcome (FD-PRO) demonstrates robust measurement properties for assessing symptom severity in Fabry disease
por: Hamed, Alaa, et al.
Publicado: (2021)

Cardiomyopathy and kidney function in agalsidase beta‐treated female Fabry patients: a pre‐treatment vs. post‐treatment analysis
por: Wanner, Christoph, et al.
Publicado: (2020)

Lyso-Gb3 Increases αvβ3 Integrin Gene Expression in Cultured Human Podocytes in Fabry Nephropathy
por: Trimarchi, Hernán, et al.
Publicado: (2020)

Will the FAbry STabilization indEX make its way to everyday clinical practice?
por: Cairns, Tereza, et al.
Publicado: (2018)

Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy
por: Warnock, David G, et al.
Publicado: (2015)

Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications
por: Weidemann, F, et al.
Publicado: (2013)

A Distinct Urinary Biomarker Pattern Characteristic of Female Fabry Patients That Mirrors Response to Enzyme Replacement Therapy
por: Kistler, Andreas D., et al.
Publicado: (2011)

Prevalence of Fabry disease in male dialysis patients: Argentinean screening study
por: Frabasil, Joaquín, et al.
Publicado: (2019)

Interaction of Fabry Disease and Diabetes Mellitus: Suboptimal Recruitment of Kidney Protective Factors
por: Sanchez-Niño, Maria D., et al.
Publicado: (2023)

X‐chromosomal inactivation patterns in women with Fabry disease
por: Wagenhäuser, Laura, et al.
Publicado: (2022)

Fabry disease: Four case reports of meningioma and a review of the literature on other malignancies
por: Thurberg, Beth L., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_gjr0d2s077nlq3tp52bvtagrq9